ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+13.5%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$71.7M
AUM Growth
+$71.7M
(+33%)
Cap. Flow
+$10.9M
Cap. Flow
% of AUM
15.14%
Top 10 Holdings %
Top 10 Hldgs %
66.95%
Holding
32
New
12
Increased
6
Reduced
9
Closed
5
Top Buys
| 1 |
GSK
GSK
|
$3.77M |
| 2 |
Sarepta Therapeutics
SRPT
|
$2.58M |
| 3 |
Inogen
INGN
|
$2.51M |
| 4 |
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
|
$2.5M |
| 5 |
UnitedHealth
UNH
|
$1.6M |
Top Sells
| 1 |
IPXL
Impax Laboratories, Inc.
IPXL
|
$2.2M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$1.29M |
| 3 |
DaVita
DVA
|
$1.25M |
| 4 |
Incyte
INCY
|
$990K |
| 5 |
Edwards Lifesciences
EW
|
$956K |
Sector Composition
| 1 | Healthcare | 90.17% |
| 2 | Industrials | 6.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
PTC Therapeutics
PTCT
$3.92B
| $6.1M | 8.51% | 620,334 +135,755 | +28% | +$1.34M |
|
2
Centene
CNC
$14.3B
| $5.61M | 7.82% | 78,680 -10,889 | -12% | -$776K |
|
|
SGYP
3
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $5.09M | 7.09% | 1,091,768 +536,683 | +97% | +$2.5M |
|
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $4.89M | 6.82% | 33,691 -8,906 | -21% | -$1.29M |
|
|
HMSY
5
DELISTED
HMS Holdings Corp.
HMSY
| $4.84M | 6.74% | 237,802 -26,958 | -10% | -$548K |
|
6
Bio-Rad Laboratories Class A
BIO
$8.06B
| $4.53M | 6.31% | 22,713 +4,395 | +24% | +$876K |
|
7
Amicus Therapeutics
FOLD
$2.34B
| $4.53M | 6.31% | 634,865 -121,731 | -16% | -$868K |
|
8
Eli Lilly
LLY
$657B
| $4.51M | 6.28% | 53,583 -3,401 | -6% | -$286K |
|
|
9
UnitedHealth
UNH
$281B
| $4.17M | 5.81% | 25,392 +9,733 | +62% | +$1.6M |
|
|
10
GSK
GSK
$79.9B
| $3.77M | 5.26% | +89,515 | New | +$3.77M |
|
11
Quest Diagnostics
DGX
$20.3B
| $3.67M | 5.12% | 37,385 +7,900 | +27% | +$776K |
|
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $2.58M | 3.6% | +87,180 | New | +$2.58M |
|
|
NVRO
13
DELISTED
NEVRO CORP.
NVRO
| $2.56M | 3.57% | 27,318 -1,407 | -5% | -$132K |
|
|
14
Inogen
INGN
$216M
| $2.51M | 3.5% | +32,393 | New | +$2.51M |
|
|
AERI
15
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $2.21M | 3.09% | 48,800 -15,295 | -24% | -$694K |
|
|
16
Incyte
INCY
$16.5B
| $1.73M | 2.41% | 12,931 -7,406 | -36% | -$990K |
|
17
Puma Biotechnology
PBYI
$254M
| $1.58M | 2.21% | +42,524 | New | +$1.58M |
|
18
Ironwood Pharmaceuticals
IRWD
$214M
| $1.4M | 1.95% | 81,852 +24,489 | +43% | +$418K |
|
19
Biogen
BIIB
$19.4B
| $840K | 1.17% | +3,073 | New | +$840K |
|
|
ALDR
20
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $826K | 1.15% | +39,696 | New | +$826K |
|
21
Syndax Pharmaceuticals
SNDX
$1.41B
| $824K | 1.15% | +60,087 | New | +$824K |
|
22
Cardinal Health
CAH
$35.5B
| $819K | 1.14% | +10,049 | New | +$819K |
|
23
AstraZeneca
AZN
$248B
| $773K | 1.08% | +24,809 | New | +$773K |
|
24
Acadia Healthcare
ACHC
$2.12B
| $519K | 0.72% | +11,915 | New | +$519K |
|
|
KERX
25
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $421K | 0.59% | +68,381 | New | +$421K |
|